Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD
© 2021 International Society of Nephrology. Published by Elsevier Inc..
INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD).
METHODS: This was a phase III, active-controlled, multicenter, partially randomized, open-label study in Japanese patients with NDD CKD. Patients who had used recombinant human erythropoietin or darbepoetin alfa (DA) before conversion were randomized to roxadustat or DA (comparative arms). Patients who had used epoetin beta pegol before conversion were allocated to roxadustat (reference arm). The primary endpoint was change in average hemoglobin (Hb) level from baseline during the evaluation period (Weeks 18-24). Longer term efficacy and safety were evaluated in roxadustat-treated patients over 52 weeks.
RESULTS: In this study, 334 patients were randomized/allocated to receive treatment (n = 132, roxadustat [comparative]; n = 131, DA [comparative]; n = 71, roxadustat [reference]). The estimated difference between the roxadustat (comparative) and DA (comparative) groups in the least squares mean of change of average Hb levels of Weeks 18 to 24 from baseline was -0.07 g/dl, with the lower limit of 95% confidence interval of -0.23 g/dl, thereby confirming the noninferiority of roxadustat to DA. Common treatment-emergent adverse events (≥3% of patients in any treatment group) observed during the 24-week treatment period included nasopharyngitis, CKD, hyperkalemia, and hypertension.
CONCLUSION: Roxadustat maintained Hb within 10 to 12 g/dl in NDD CKD patients and was noninferior to DA. The safety profiles observed in this study are consistent with previous studies performed in this patient population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Kidney international reports - 6(2021), 7 vom: 23. Juli, Seite 1810-1828 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akizawa, Tadao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Active comparator |
|---|
| Anmerkungen: |
Date Revised 25.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ekir.2021.04.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328528048 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328528048 | ||
| 003 | DE-627 | ||
| 005 | 20231225203122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ekir.2021.04.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328528048 | ||
| 035 | |a (NLM)34307976 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akizawa, Tadao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 International Society of Nephrology. Published by Elsevier Inc. | ||
| 520 | |a INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD) | ||
| 520 | |a METHODS: This was a phase III, active-controlled, multicenter, partially randomized, open-label study in Japanese patients with NDD CKD. Patients who had used recombinant human erythropoietin or darbepoetin alfa (DA) before conversion were randomized to roxadustat or DA (comparative arms). Patients who had used epoetin beta pegol before conversion were allocated to roxadustat (reference arm). The primary endpoint was change in average hemoglobin (Hb) level from baseline during the evaluation period (Weeks 18-24). Longer term efficacy and safety were evaluated in roxadustat-treated patients over 52 weeks | ||
| 520 | |a RESULTS: In this study, 334 patients were randomized/allocated to receive treatment (n = 132, roxadustat [comparative]; n = 131, DA [comparative]; n = 71, roxadustat [reference]). The estimated difference between the roxadustat (comparative) and DA (comparative) groups in the least squares mean of change of average Hb levels of Weeks 18 to 24 from baseline was -0.07 g/dl, with the lower limit of 95% confidence interval of -0.23 g/dl, thereby confirming the noninferiority of roxadustat to DA. Common treatment-emergent adverse events (≥3% of patients in any treatment group) observed during the 24-week treatment period included nasopharyngitis, CKD, hyperkalemia, and hypertension | ||
| 520 | |a CONCLUSION: Roxadustat maintained Hb within 10 to 12 g/dl in NDD CKD patients and was noninferior to DA. The safety profiles observed in this study are consistent with previous studies performed in this patient population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a active comparator | |
| 650 | 4 | |a anemia | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a conversion | |
| 650 | 4 | |a non–dialysis dependent | |
| 650 | 4 | |a roxadustat | |
| 700 | 1 | |a Iwasaki, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuka, Tetsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Reusch, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international reports |d 2016 |g 6(2021), 7 vom: 23. Juli, Seite 1810-1828 |w (DE-627)NLM264185072 |x 2468-0249 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:7 |g day:23 |g month:07 |g pages:1810-1828 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ekir.2021.04.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 7 |b 23 |c 07 |h 1810-1828 | ||